Search results
Showing 166 to 180 of 250 results for carcinoma
Irreversible electroporation for primary liver cancer (IPG664)
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.
View recommendations for IPG664Show all sections
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.
View recommendations for IPG135Show all sections
Sections for IPG135
Interstitial photodynamic therapy for malignant parotid tumours (IPG259)
Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.
View recommendations for IPG259Show all sections
Sections for IPG259
Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.
View recommendations for IPG290Show all sections
Sections for IPG290
Evidence-based recommendations on laparoscopic deroofing of simple renal cysts. This involves draining the cyst and removing part of the cyst wall through small cuts in the abdomen (keyhole surgery).
View recommendations for IPG226Show all sections
Sections for IPG226
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.
Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.
This quality standard covers diagnosing and managing bladder cancer in adults (aged 18 and over) referred from primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS106Show all sections
Sections for QS106
- Quality statements
- Quality statement 1: Obtaining detrusor muscle during transurethral resection of bladder tumour
- Quality statement 2: Chemotherapy during transurethral resection of bladder tumour
- Quality statement 3: Access to a clinical nurse specialist
- Quality statement 4: Risk classification
- Quality statement 5: Discussing treatment options for high-risk non-muscle-invasive bladder cancer
- Quality statement 6: Discussing treatment options for muscle-invasive urothelial bladder cancer
- Quality statement 7: Discharge to primary care
Irreversible electroporation for treating renal cancer (IPG443)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for IPG443Show all sections
Sections for IPG443
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for IPG691Show all sections
High-intensity focused ultrasound for prostate cancer (IPG118)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
In development [GID-TA11074] Expected publication date: TBC